29,70 €
0,18 %gestern
L&S, 26. Februar, 22:54 Uhr
ISIN
US23257D1037
Symbol
CBAY
Berichte
Sektor
Industrie

CymaBay Therapeutics, Inc. Aktie News

Neutral
PRNewsWire
5 Tage alt
-  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo -  NEWARK, Calif.
Neutral
GlobeNewsWire
6 Tage alt
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the “Grant Date”) in connection with the employees' commencement of employment at ...
Neutral
Business Wire
10 Tage alt
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay Therapeutics, Inc. (NasdaqGS: CBAY) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of CymaBay will receive $32.50 in cash for each share of CymaBay tha...
Positiv
Investopedia
14 Tage alt
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.
Neutral
PRNewsWire
14 Tage alt
MILWAUKEE , Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY)  for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead. Click here to learn how to join the https://www.ademilaw.com/case/cymabay-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
Positiv
InvestorPlace
14 Tage alt
CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.
Positiv
WSJ
14 Tage alt
CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.
Neutral
Business Wire
14 Tage alt
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) to Gilead Sciences, Inc. for $32.50 per share in cash is fair to CymaBay shareholders. Halper Sadeh encourages CymaBay shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (2...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen